The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Epidemiology of Neuroendocrine Tumours
Abstract
Neuroendocrine tumours account for only 0.5% of all malignancies. The incidence is approximately 2/100,000 with a female preponderance under the age of 50 years due to appendiceal location. The main primary sites are the gastrointestinal tract (62–67%) and the lung (22–27%). Presentation with metastatic disease accounts for 12–22%. In the last decades, the incidence has been rising. This might be due to more awareness, improved diagnostic tools or a change in definition. Most neuroendocrine tumours are mainly sporadic, but association with the multiple endocrine neoplasia type 1 syndrome and clustering within families is known. Also an increased risk of secondary cancers has been reported, but numbers are small. The 5-year survival is mainly associated with stage: 93% in local disease, 74% in regional disease and 19% in metastatic disease. In metastatic disease, survival increased since 1992, when treatment with octreotide became largely available in the Netherlands.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A 5‐decade analysis of 13,715 carcinoid tumors
Modlin, I. M., Lye, K. D., & Kidd, M. (2003) · Cancer · doi:10.1002/cncr.11105 · Cited by 2,734
van Leeuwen, F. E., Klokman, W. J., Veer, M. B. V., Hagenbeek, A., Krol, A. D. G., Vetter, U. A. O., Schaapveld, M., van Heerde, P., Burgers, J. M. V., Somers, R., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.3.487 · Cited by 436
Incidence trends and risk factors of carcinoid tumors: A nationwide epidemiologic study from Sweden
Hemminki, K., & Li, X. (2001) · Cancer · doi:10.1002/1097-0142(20011015)92:8<2204::aid-cncr1564>3.0.co;2-r · Cited by 363
Epidemiology and survival in patients with carcinoid disease in the Netherlands
Quaedvlieg, P. F. H. J., Visser, O., Lamers, C. B. H. W., Janssen-Heijen, M. L. G., & Taal, B. G. (2001) · Annals of Oncology · doi:10.1023/a:1012272314550 · Cited by 260
Self-citationFamilial carcinoid tumors and subsequent cancers: A nation-wide epidemiologic study from Sweden
Hemminki, K., & Li, X. (2001) · International Journal of Cancer · doi:10.1002/ijc.1473 · Cited by 130
Palliative effect of metaiodobenzylguanidine in metastatic carcinoid tumors.
Taal, B. G., Hoefnagel, C. A., Olmos, R. A. V., Boot, H., & Beijnen, J. H. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.6.1829 · Cited by 121
Self-citationEpidemiology, clinical features and diagnosis of gastroenteropancreatic endocrine tumours
Tomassetti, P., Migliori, M., Lalli, S., Campana, D., Tomassetti, V., & Corinaldesi, R. (2001) · Annals of Oncology · doi:10.1093/annonc/12.suppl_2.s95 · Cited by 109
Nguyen, A. P., Schaff, H. V., & Connolly, H. M. (2020) · Springer eBooks · doi:10.1007/978-3-030-24174-2_51 · Cited by 104
The epidemiology of carcinoid tumours in England and Scotland
Newton, J. N., Swerdlow, A. J., Silva, I. D. S., Vessey, M., Grahame‐Smith, D., Primatesta, P., & Reynolds, D. (1994) · British Journal of Cancer · doi:10.1038/bjc.1994.424 · Cited by 102
Epidemiology of carcinoid neoplasms in Vaud, Switzerland, 1974–97
Levi, F., Te, V.-C., Randimbison, L., et al. (2000) · British Journal of Cancer · doi:10.1054/bjoc.2000.1394 · Cited by 90
Cited by
Nothing But NET: A Review of Neuroendocrine Tumors and Carcinomas
Oronsky, B., Ma, P. C., Morgensztern, D., & Carter, C. A. (2017) · Neoplasia · doi:10.1016/j.neo.2017.09.002 · Cited by 763
Niederle, M. B., Hackl, M., Kaserer, K., & Niederle, B. (2010) · Endocrine-Related Cancer · doi:10.1677/erc-10-0152 · Cited by 444
Panzuto, F., Nasoni, S., Falconi, M., Corleto, V. D., Capurso, G., Cassetta, S., Di Fonzo, M., Tornatore, V., Milione, M., Angeletti, S., et al. (2005) · Endocrine-Related Cancer · doi:10.1677/erc.1.01017 · Cited by 391
Clinical Biology of the Pituitary Adenoma
Melmed, S., Kaiser, U. B., Lopes, M. B., Bertherat, J., Syro, L. V., Raverot, G., Reincke, M., Johannsson, G., Beckers, A., Fleseriu, M., et al. (2022) · Endocrine Reviews · doi:10.1210/endrev/bnac010 · Cited by 321
Ambrosini, V., Tomassetti, P., Castellucci, P., Campana, D., Montini, G., Rubello, D., Nanni, C., Rizzello, A., Franchi, R., & Fanti, S. (2008) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-008-0769-2 · Cited by 266
Shi, M., Jakobsson, V., Greifenstein, L., Khong, P.-L., Chen, X., Baum, R. P., & Zhang, J. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.1034315 · Cited by 68
“Despite the success of [90Y]Y-DOTATOC and [177Lu]LuDOTATATE in the treatment of NETs in terms of progressionfree survival, there were problems with 90Y concerning renal toxicity and a low rate of complete remissions, suggesting an improvement in PRRT efficacy is required (27, 41) with the main aspects of (1) identific…”
BackgroundGhrelin in neuroendocrine organs and tumours
Leontiou, C. A., Franchi, G., & Korbonits, M. (2007) · Pituitary · doi:10.1007/s11102-007-0023-0 · Cited by 40
Metadata
- Authors
- Taal, B. G., & Visser, O.
- Venue
- Neuroendocrinology
- Publisher
- S. Karger AG
- Published
- 2004
- Volume
- 80
- Issue
- Suppl. 1
- Pages
- 3-7
- ISSN
- 0028-3835 (ISSN-L)
- 1423-0194
- OpenAlex
- W2053825882
- Cited by
- 381
- References
- 11
- FWCI
- 3.83
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.